SCHEMBL6401560

SCHEMBL6401560

CCN(Cc1ccccc1F)c1nc(O)nc(Nc2ccc3ncsc3c2)n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.55
KDR P35968 6/20 0.49
INSR P06213 3/20 0.49
TEK Q02763 3/20 0.49
CSF1R P07333 2/20 0.49
PDGFRB P09619 2/20 0.49
PDGFRA P16234 2/20 0.49
SYK P43405 1/20 0.42
PFKFB3 Q16875 1/20 0.41
IKBKB O14920 5/20 0.40
CHUK O15111 1/20 0.40
TERT O14746 1/20 0.38
TOP2A P11388 1/20 0.38
JAK3 P52333 2/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
BTK Q06187 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321519 0.87 KDR (0.51) CFTRKDRINSRTEKCSF1R
SCHEMBL6399454 0.87 KDR (0.65) CFTRKDRINSRTEKCSF1R
SCHEMBL6395289 0.84 CFTR (0.54) CFTRKDRINSRTEKCSF1R
SCHEMBL6394926 0.84 CFTR (0.42) CFTRKDRINSRTEKCSF1R
SCHEMBL6398204 0.83 KDR (0.56) CFTRKDRINSRTEKCSF1R
SCHEMBL6400459 0.82 PFKFB3 (0.52) CFTRKDRINSRTEKCSF1R
SCHEMBL6729223 0.80 KDR (0.57) CFTRKDRINSRTEKCSF1R
SCHEMBL6321516 0.80 KDR (0.55) CFTRKDRINSRTEKCSF1R
SCHEMBL6404350 0.78 KDR (0.54) CFTRKDRINSRTEKCSF1R
SCHEMBL6397238 0.78 KDR (0.51) CFTRKDRINSRTEKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US claimed
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP disclosed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US disclosed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 CFTR 3616/4885KDR 2/4885INSR 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.